Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EM01 Idelalisib
D10560 Idelalisib (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Idelalisib
D10560 Idelalisib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
D10560 Idelalisib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10560 Idelalisib
DG02924 UGT substrate
DG03182 UGT1A4 substrate
D10560 Idelalisib
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Phosphotransferase
PIK3CD
D10560 Idelalisib (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10560
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10560
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10560
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10560